911 Improved lifelines needed for all lines: real-world treatment patterns and attrition rates in US patients with non-driver mutation metastatic non-small cell lung cancer

• Chen Hu,
• Charlene Wong,
• Iftekhar Kalsekar,
• Qing Huang,
• Aisha Hasan,
• Josephine Feliciano,
• Adam Schoenfeld,
• Ravi Rajaram,
• Urmila Chandran,
• U Hariharan,
• Tianyi Wang

Affiliations

Chen Hu

6 Division of Quantitative Sciences, Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA

Charlene Wong

1 Singapore Eye Research Institute, Singapore, Singapore

Iftekhar Kalsekar

Medical Device Epidemiology, Johnson and Johnson Medical Devices, New Brunswick, New Jersey, USA

Qing Huang

6Johnson and Johnson External Innovation, New Brunswick, NJ, USA

Aisha Hasan

1GlaxoSmithKline, Collegeville, PA, USA

Josephine Feliciano

Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Adam Schoenfeld

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Ravi Rajaram

1Department of Surgery and Center for Healthcare Studies in the Institute for Public Health and Medicine, Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois, USA

Urmila Chandran

4Janssen Research and Development LLC., Raritan, NJ, USA

U Hariharan

5Johnson and Johnson, Titusville, NJ, USA

Tianyi Wang

4Janssen Research and Development LLC., Raritan, NJ, USA